Bright Peak Presents New Therapeutics Highlighted by Multifunctional PD-1 Targeted Immunocytokines at SITC 2022
– BPT567, a first-in-class PD1-IL18 immunocytokine, delivers coordinated PD-1 blockade and potent IL-18 signaling to PD-1+ T effector cells resulting in striking antitumor activity – – BPT331, a PD1-IL2 cis-signaling immunocytokine with potent best-in-class properties – – Innovative chemical conjugation